Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16167
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPasman, Yfke-
dc.contributor.authorSoliman, Caroline-
dc.contributor.authorRamsland, Paul A-
dc.contributor.authorKaushik, Azad K-
dc.date2016-08-03-
dc.date.accessioned2016-08-26T01:21:14Z-
dc.date.available2016-08-26T01:21:14Z-
dc.date.issued2016-09-
dc.identifier.citationMolecular Immunology 2016; 77: 113-125en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16167-
dc.description.abstractWe discovered that some bovine antibodies are amongst the largest known to exist due to the presence of an exceptionally long CDR3H (≥49 amino acids) with multiple cysteines that provide a unique knob and stalk structure to the antigen binding site. The large CDR3H size, unlike mouse and human, provides a suitable platform for antigenization with large configurational B-epitopes. Here we report the identification of a B-epitope on the gC envelope protein of bovine herpes virus type-1 (BoHV-1) recognized by a bovine IgG1 antibody. The identified 156 amino acid long gC fragment (gC156) was expressed as a recombinant protein. Subsequently, a functional scFv fragment with a 61 amino-acid long CDR3H (scFv1H12) was expressed such that gC156 was grafted into the CDR3H, replacing the "knob" region (gC156scFv1H12 or Ag-scFv). Importantly, the Ag-scFv could be recognized by a neutralizing antibody fragment (scFv3-18L), which suggests that the engraftment of gC156 into the CDR3H of 1H12 maintained the native conformation of the BoHV-1 B-epitope. A 3D model of gC156 was generated using fold-recognition approaches and this was grafted onto the CDR3H stalk of the 1H12 Fab crystal structure to predict the 3D structure of the Ag-scFv. The grafted antigen in Ag-scFv is predicted to have a compact conformation with the ability to protrude into the solvent. Upon immunization of bovine calves, the antigenized scFv (gC156scFv1H12) induced a higher antibody response as compared to free recombinant gC156. These observations suggest that antigenization of bovine scFv with an exceptionally long CDR3H provides a novel approach to developing the next generation of vaccines against infectious agents that require induction of protective humoral immunity.en_US
dc.subjectAntibodyen_US
dc.subjectAntigenized scFven_US
dc.subjectB epitopeen_US
dc.subjectBoHV-1en_US
dc.subjectCDR3en_US
dc.subjectExceptionally long CDR3Hen_US
dc.subjectH graften_US
dc.subjectscFven_US
dc.titleExceptionally long CDR3H of bovine scFv antigenized with BoHV-1 B-epitope generates specific immune response against the targeted epitopeen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMolecular Immunologyen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canadaen_US
dc.identifier.affiliationSchool of Science, RMIT University, Bundoora, Victoria, Australiaen_US
dc.identifier.affiliationCentre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Immunology, Alfred Medical Research and Education Precinct, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Surgery, Austin Health, University of Melbourne, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27497190en_US
dc.identifier.doi10.1016/j.molimm.2016.07.014en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherRamsland, Paul A
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptSurgery (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

12
checked on Nov 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.